Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (450)	12/9/1999 12:43:00 AM
From: Pseudo Biologist	Read Replies (1) \| Respond to of 666

For NHL, yes they were using Rituxan. But I think they are looking at other cancers and for at least one of those they have their own humanized Ab (and I seem to recall they were trying to make it or a fragment thereof in plants). Sorry for being vague, home page of co. seems to be down and I am too tired now to swim through the SEC stuff. Obligatory Coulter comment: This is a nice post from Yahoo! land; summarizes expected toxicities of different treatments (patient perspective): messages.yahoo.com PB

To: scaram(o)uche who wrote (450)	12/9/1999 12:36:00 PM
From: tnsaf	Read Replies (1) \| Respond to of 666

<<We once concluded that NERX was using C2B8 for initial studies>> The table of clinical trials lists it as C2B8-SA,90Y-B. There is a reference listed as "Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma: preliminary results [abstract] J Nucl Med 1999, 40:19", but I can't find it listed on the Journal of Nuclear Medicine's web site for Jan - Nov. The page number indicates it should be in the January issue. Too bad they aren't listed on Saturday's Informed Investors in Seattle, or Mike could ask about it. Jason